Smith & Nephew SNATS (NYSE:SNN – Get Free Report) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks reports.
Several other equities analysts also recently commented on SNN. Wall Street Zen downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Saturday, September 5th. Bank of America downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a research report on Tuesday. Weiss Ratings upgraded Smith & Nephew SNATS from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, September 4th. Canaccord Genuity Group decreased their target price on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research note on Monday, May 11th. Finally, BTIG Research initiated coverage on shares of Smith & Nephew SNATS in a research report on Monday, August 31st. They issued a “neutral” rating on the stock. One investment analyst has rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Smith & Nephew SNATS presently has an average rating of “Hold” and an average price target of $30.93.
Get Our Latest Analysis on Smith & Nephew SNATS
Smith & Nephew SNATS Stock Performance
Institutional Investors Weigh In On Smith & Nephew SNATS
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Clearstead Trust LLC bought a new stake in shares of Smith & Nephew SNATS in the 2nd quarter worth approximately $25,000. Arax Advisory Partners increased its holdings in shares of Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 569 shares in the last quarter. Advisors Asset Management Inc. acquired a new stake in shares of Smith & Nephew SNATS during the 4th quarter valued at $36,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Smith & Nephew SNATS in the 3rd quarter worth $41,000. Finally, Addison Advisors LLC acquired a new stake in shares of Smith & Nephew SNATS during the second quarter worth $43,000. 25.64% of the stock is owned by institutional investors and hedge funds.
About Smith & Nephew SNATS
Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.
In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.
Read More
- Five stocks we like better than Smith & Nephew SNATS
- Life Time Keeps Beating Expectations, But Insiders Are Selling Into Strength
- Sezzle’s BNPL Growth Is Working, But the Stock Comes With a Catch
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
Receive News & Ratings for Smith & Nephew SNATS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS and related companies with MarketBeat.com's FREE daily email newsletter.
